Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is trading in the green early this morning, and for good reason. The company announced the presentation of positive data, exciting investors who are pushing the stock up. Today, we’ll talk about:
- The data;
- what we’re seeing from CYCC stock as a result; and
- what we’ll be watching for ahead.
CYCC Gains On Data Presentation
As mentioned above, Cyclacel Pharmaceuticals is having a great day in the market this morning after announcing the presentation of data. The announcement came early in the pre-market this morning via press release.
In the release, the company said that data from a Phase 1 clinical study of the company’s DNA damage response program with an oral, sequential regimen of sapacitabine and seliciclib was recently presented. The combination treatment is being assessed as an option for patients with BRCA mutant metastatic breast cancer.
In the release, CYCC said that the data was presented at the 2019 American Association for Cancer Research Annual Meeting. The data demonstrated that the regimen was safe and led to a clinical benefit rate of 30%.
In fact, all eight PARP inhibitor naive patients, working out to about half of patients previously treated with platinum agents and one previous PARP inhibitor responded. Moreover progression on previous platinum PARP inhibitors was associated with lack of benefit.
Based on the data, the investigators are now enrolling a Phase 1b/2 study of sapacitabine in combination with a PARP inhibitor in PARP inhibitor-naive patients with BRCA mutant breast cancer.
In a statement, Sara M. Tolaney, MD, MPH, Senior Physician, Director of Clinical Trials and Breast Oncology at the Dana-Farber Cancer Institute in Boston and Principal Investigator on the CYCC study, had the following to offer:
We are encouraged by the durable responses and stable disease in PARP inhibitor-naïve patients with BRCA mutant metastatic breast cancer. We are very excited about the ongoing evaluation of the combination of sapacitabine and the PARP inhibitor olaparib in PARP inhibitor-naïve patients with metastatic BRCA mutant breast cancer.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. In the case of Cyclacel Pharmaceuticals, the news proved to be overwhelmingly positive.
After all, not only did the data show clinical benefit and that the treatment was safe and well-tolerated, it opened the door to further development, pushing the treatment closer to potential commercialization. So, it’s not surprising to see that excited investors are sending the stock on a run up.
As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:53), CYCC is trading at $0.95 per share after a gain of $0.015 per share or 1.58% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CYCC. In particular, we’re interested in following the story surrounding the company’s continued work to develop this candidate as results seem to be promising. Nonetheless, we’ll keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!